Valuation : ADC Therapeutics SA

Market Cap 146M 126M 118M 108M 202M 13.88B 203M 1.4B 545M 7.02B 546M 534M 23.29B P/E 2026 *
-1.5x
P/E 2027 * -1.68x
Enterprise Value 146M 126M 118M 108M 202M 13.88B 203M 1.4B 545M 7.02B 546M 534M 23.29B EV / Sales 2026 *
1.8x
EV / Sales 2027 * 1.43x
Free-Float
83.9%
Yield 2026 *
-
Yield 2027 * -
1 day+1.79%
1 week+14.39%
Current month+8.57%
1 month+2.70%
3 months-66.96%
6 months-72.20%
Current year-67.71%
1 week 0.95
Extreme 0.9514
1.17
1 month 0.94
Extreme 0.9393
1.23
Current year 0.78
Extreme 0.7796
4.98
1 year 0.78
Extreme 0.7796
4.98
3 years 0.36
Extreme 0.359908
6.04
5 years 0.36
Extreme 0.359908
32
10 years 0.36
Extreme 0.359908
56.59
Manager TitleAgeSince
Chief Executive Officer 53 08/05/2022
Director of Finance/CFO 54 18/12/2022
Chief Tech/Sci/R&D Officer 52 30/09/2024
Director TitleAgeSince
Director/Board Member 67 31/05/2019
Director/Board Member 53 31/05/2018
Chairman 59 29/02/2020
Date Insider Type Main position Quantity % Market Cap.
30/06/26 Free

Chief Executive Officer

675,000 0.5307%
30/06/26 Free

Chief Financial Officer

203,700 0.1602%
30/06/26 Free

Chief Technology Officer

213,900 0.1682%
Change 5-day change 1-year change 3-year change Capi.($)
+1.79%+14.39%-64.92%-8.80% 146M
-1.59%-3.35%+64.49%+98.69% 69.54B
-1.34%-0.75%+48.56%+90.63% 64.97B
-8.37%-12.43%+0.14%-15.42% 25.64B
-2.35%-5.75%-12.17%+448.29% 25.89B
+0.30%-0.69%+63.18%+11.93% 26.51B
-0.96%+10.36%+278.86%+438.78% 20.22B
-0.51%+0.23%+33.71%-18.02% 19.98B
-1.91%-4.37%+13.33%+531.29% 15.69B
-1.47%+0.68%+43.67%+145.49% 13.49B
Average -1.64%-0.29%+46.88%+172.29% 28.21B
Weighted average by Cap. -1.93%-1.49%+57.09%+152.74%

Financials

2026 *2027 *
Net sales 80.65M 69.62M 65.27M 59.59M 112M 7.69B 113M 774M 302M 3.89B 303M 296M 12.91B 102M 88.03M 82.52M 75.34M 142M 9.73B 142M 978M 382M 4.92B 383M 374M 16.32B
Net income -120M -103M -97.01M -88.57M -167M -11.43B -167M -1.15B -449M -5.78B -450M -440M -19.18B -118M -102M -95.3M -87.01M -164M -11.23B -164M -1.13B -441M -5.68B -442M -432M -18.84B
Net Debt - -
Logo ADC Therapeutics SA
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
Employees
191
Date Price Change Volume
28/08/26 US$1.140 +1.79% 2,577,910
27/08/26 US$1.120 +6.67% 1,403,771
26/08/26 US$1.050 +0.96% 1,947,239
25/08/26 US$1.040 +7.76% 3,927,974
24/08/26 US$0.9651 -3.16% 640,512
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.140USD
Average target price
3.333USD
Spread / Average Target
+192.40%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADCT Stock